Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Qiagen ( (QGEN) ) has issued an update.
QIAGEN has disclosed a managers’ transaction involving board member Ross Levine, whose shareholding was affected by the company’s previously announced synthetic share repurchase program. Under the terms of the program, every 20 issued QIAGEN shares were consolidated into 19, resulting in Levine’s stake being adjusted by 1,004 shares to a total of 19,072 common shares, with the transaction carried out outside a trading venue on January 7, 2026. The consolidation, part of a broader capital-structure measure approved by shareholders, effectively reduces the number of shares outstanding while maintaining proportional ownership, signaling continued execution of QIAGEN’s shareholder-return and balance-sheet optimization strategy.
The most recent analyst rating on (QGEN) stock is a Hold with a $48.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V. is a life sciences and diagnostics company headquartered in Venlo, Netherlands, whose shares are listed on multiple European exchanges as well as the NYSE and Swiss markets. The company focuses on molecular testing solutions, including sample and assay technologies used in research, clinical diagnostics and applied testing, serving laboratories, healthcare providers and biotech and pharmaceutical customers globally.
Average Trading Volume: 1,155,025
Technical Sentiment Signal: Strong Buy
Current Market Cap: $9.99B
For a thorough assessment of QGEN stock, go to TipRanks’ Stock Analysis page.